ARDS

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus. The company's developmental efforts extend to AR-105, a fully human IgG1 mAb in Phase II trials, which is being developed to combat the gram-negative bacterium P. aeruginosa. Furthermore, AR-101, a human IgM mAb, is undergoing Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) specifically linked to P. aeruginosa serotype O11. In earlier stages, AR-401 is in preclinical development to address infections caused by Acinetobacter baumannii, and AR-201, a fully human IgG1 mAb, is in a preclinical program targeting respiratory syncytial virus. AR-501, an anti-infective therapy, is currently in Phase I/IIa clinical trials for managing chronic lung infections in patients with cystic fibrosis. Additionally, Aridis is developing AR-712 and AR-701, a combination of two fully human IgG1 mAbs, which is in Phase I/II clinical trials for treating mild to moderate COVID-19 in non-hospitalized individuals. Aridis Pharmaceuticals, Inc. was established in 2003 and is headquartered in Los Gatos, California.